Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors
Zavondemstat was very well tolerated and showed encouraging preliminary clinical benefit in heavily pretreated patients with advanced cancer. Continued evaluation of zavondemstat is warranted.
Authors
- Mehmet A. Baysal (ORCID: https://orcid.org/0000-0002-8446-6531)
- Farshid Dayyani (ORCID: https://orcid.org/0000-0002-4970-5189)
- Abhijit Chakraborty (ORCID: https://orcid.org/0000-0002-3822-5657)
- Apostolia M. Tsimberidou (ORCID: https://orcid.org/0000-0003-2713-233X)
- David Sommerhalder (ORCID: https://orcid.org/0000-0002-7033-9064)
- Jason T. Henry (ORCID: https://orcid.org/0000-0003-1991-4227)
- Cesar A. Perez (ORCID: https://orcid.org/0000-0001-5860-4921)
- Meredith S. Pelster
- Andrae Lavon Vandross
- Chandtip Chandhasin
- Yiyun Dai
- Ivan King
- Frank Perabo
- S. Tu
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Sarah Cannon Research Institute (GB)
- University of California, Irvine (US)
- Texas Oncology (US)
- University of California, Irvine Medical Center (US)
- Sarah Cannon (US)
- Florida Cancer Specialists & Research Institute (US)
- HealthONE (US)
- Io Therapeutics (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-06-28
- DOI
- https://doi.org/10.1093/oncolo/oyaf169
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 3.75
Funders
- California Institute for Regenerative Medicine
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Gilead Sciences
- Exelixis
- Novocure
- Parker Institute for Cancer Immunotherapy
- Mirati Therapeutics
- BeiGene
- NGM Biopharmaceuticals
- Revolution Medicines
- Ascentage Pharma
- MacroGenics
- Eisai
- Novo Nordisk
- Astellas Pharma
- Ipsen
- Symphogen
- Sirtex Medical
- National Institutes of Health
- Genentech
- University of Texas MD Anderson Cancer Center
- National Cancer Institute